Drug Profile

Research programme: gut-microbiome based therapeutics - Axial Therapeutics/Seed Health

Latest Information Update: 22 Jul 2022

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Axial Therapeutics; Seed Health
Class Antidepressants; Anxiolytics; Bacteria
Mechanism of Action Bacteria replacements; Gastrointestinal microbiome modulators

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

13 Jul 2022 Axial Therapeutics and Seed Health agree to co-promote and co-develop gut-microbiome based therapeutics for Anxiety disorders, Depressive disorders and Traumatic stress disorders
13 Jul 2022 Early research in Anxiety disorders in USA (unspecified route)
13 Jul 2022 Early research in Depressive disorders in USA (unspecified route)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com